Literature DB >> 2764209

Sample size and power based on the population attributable fraction.

W S Browner1, T B Newman.   

Abstract

Most methods for calculating sample size use the relative risk (RR) to indicate the strength of the association between exposure and disease. For measuring the public health importance of a possible association, the population attributable fraction (PAF)--the proportion of disease incidence in a population that is attributable to an exposure--is more appropriate. We determined sample size and power for detecting a specified PAF in both cohort and case-control studies and compared the results with those obtained using conventional estimates based on the relative risk. When an exposure is rare, a study that has little power to detect a small RR often has adequate power to detect a small PAF. On the other hand, for common exposures, even a relatively large study may have inadequate power to detect a small PAF. These comparisons emphasize the importance of selecting the most pertinent measure of association, either relative risk or population attributable fraction, when calculating power and sample size.

Mesh:

Year:  1989        PMID: 2764209      PMCID: PMC1349706          DOI: 10.2105/ajph.79.9.1289

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  16 in total

1.  The occurrence of lung cancer in man.

Authors:  M L LEVIN
Journal:  Acta Unio Int Contra Cancrum       Date:  1953

2.  Epidemiology of infectious and non-infectious disease: some comparisons.

Authors:  A M Lilienfeld
Journal:  Am J Epidemiol       Date:  1973-03       Impact factor: 4.897

3.  Letter: Definitions of attributable risk.

Authors:  A Leviton
Journal:  Am J Epidemiol       Date:  1973-09       Impact factor: 4.897

4.  Estimating the impact of risk factor modification programs.

Authors:  W S Browner
Journal:  Am J Epidemiol       Date:  1986-01       Impact factor: 4.897

5.  Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men.

Authors:  M J Martin; S B Hulley; W S Browner; L H Kuller; D Wentworth
Journal:  Lancet       Date:  1986-10-25       Impact factor: 79.321

6.  The design of case-control studies: the influence of confounding and interaction effects.

Authors:  P G Smith; N E Day
Journal:  Int J Epidemiol       Date:  1984-09       Impact factor: 7.196

7.  Sample size determination in case-control studies: the influence of the distribution of exposure.

Authors:  G E McKeown-Eyssen; D C Thomas
Journal:  J Chronic Dis       Date:  1985

8.  The problem of multiple inference in studies designed to generate hypotheses.

Authors:  D C Thomas; J Siemiatycki; R Dewar; J Robins; M Goldberg; B G Armstrong
Journal:  Am J Epidemiol       Date:  1985-12       Impact factor: 4.897

9.  Introduction to sample size determination and power analysis for clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1981-06

10.  Logistic model estimation of death attributable to risk factors for cardiovascular disease in Evans County, Georgia.

Authors:  D C Deubner; W E Wilkinson; M J Helms; H A Tyroler; C G Hames
Journal:  Am J Epidemiol       Date:  1980-07       Impact factor: 4.897

View more
  1 in total

1.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.

Authors:  Ann K Daly; Peter T Donaldson; Pallav Bhatnagar; Yufeng Shen; Itsik Pe'er; Aris Floratos; Mark J Daly; David B Goldstein; Sally John; Matthew R Nelson; Julia Graham; B Kevin Park; John F Dillon; William Bernal; Heather J Cordell; Munir Pirmohamed; Guruprasad P Aithal; Christopher P Day
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.